BHV-1400 for IgA Nephropathy

Recruiting at 6 trial locations

Overseen By Chief Medical Officer

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Biohaven Therapeutics Ltd.

Disqualifiers: Secondary IgAN, Non-IgAN kidney disease

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 4 weeks

10 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Are You a Good Fit for This Trial?

This trial is for individuals who have been diagnosed with IgA Nephropathy (IgAN) through a kidney biopsy. It's not open to people whose chronic kidney disease isn't caused by IgAN or those with secondary forms of the condition.

Inclusion Criteria

Participants must have biopsy-confirmed IgA Nephropathy

Exclusion Criteria

My kidney disease is not caused by IgA nephropathy.

I have a secondary type of IgA nephropathy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BHV-1400 to assess safety and tolerability

4 weeks

Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• BHV-1400

Trial Overview The study is testing BHV-1400 to see if it's safe and can be tolerated as a treatment option for patients with IgA Nephropathy, which is a type of kidney inflammation that affects the glomeruli.

How Is the Trial Designed?

Group I: BHV-1400 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Biohaven Therapeutics Ltd.

Lead Sponsor

Trials

13

Recruited

4,800+